Learn more about what’s on the agenda for Session I of the 2026 MDS Annual Meeting
The first session of the 2026 MDS Annual Meeting delivers exactly what our community needs: expert insight on severe cutaneous adverse reactions and challenging clinical cases.
On Thursday, March 26 in Denver, Session I will feature:
SJS/TEN: Advances and Opportunities
Robert G. Micheletti, MD (University of Pennsylvania) shares the latest on diagnosis, management, and emerging therapies
Keeping It Together: Updates in Autoimmune Blistering Disorders
Brittney Schultz, MD (University of Minnesota) covers what’s new in pemphigus, pemphigoid, and related conditions
Treatment Lapses Impact Early-Stage CTCL Outcomes
Peyton Warp presents findings from a 14-year retrospective cohort study
Surgical Grafting Outcomes in Pyoderma Gangrenosum
Morgan Vague shares data on this complex treatment approach
This is the kind of focused, clinically relevant programming that makes the MDS Annual Meeting essential for anyone managing patients with serious skin disease. Explore the full agenda here.
